Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1659-1663

  Wakai, Toshifumi ^a   Shirai, Yoshio ^a   Sakata, Jun ^a   Takamura, Masaaki ^a   Matsuda, Yasunobu ^a   Korita, Pavel V ^a   Muneoka, Katsuki ^b   Sasaki, Masataka ^b   Ajioka, Yoichi ^a   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niitsu Medical Center Hospital   (Japan)

Author keywords

Gemcitabine; Intrahepatic cholangiocarcinoma; Neoadjuvant chemotherapy; Ribonucleotide reductase M1; Surgical resection

Indexed keywords

GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 83355174171     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11175     Document Type: Article

References (14)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005; 366:1303-1314. (Pubitemid 41416587)
2. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 Suppl5:v7-12.
3. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yáñez M, Gamargo C, Ahumada M: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12:1403-1406. (Pubitemid 33100245)
4. Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003; 49:154-158. (Pubitemid 36736937)
5. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22:193-198. (Pubitemid 38270476)
6. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57:647-653. (Pubitemid 43237850)
7. Jordheim LP, Sève P, Trédan O, Dumontet C: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2010 [PMID: 21163702].
8. Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K: Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep 2008; 20:279-286.
9. Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M, Kitajima Y, Tokunaga O, Noshiro H, Miyazaki K: Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. Int J Oncol 2010; 37:845-852.
10. Kim SH, Kim IH, Kim SW, Lee SO: Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. World J Gastroenterol 2009; 15:4593-4595.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
12. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 4.0. National Cancer Institute. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm.
13. Sobin LH, Gospodarowicz MK, Wittekind CH, eds: UICC. TNM Classification of Malignant Tumours. 7th edition. New York, John Wiley and Sons, Inc., 2009: 114-117.
14. Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O'Briant KC, Bepler G: Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome 1999; 10:916-922. (Pubitemid 29445383)